Jaguar Animal Health Inc (JAGX)’s Bearish Double Bottom Points to Higher Stock Risks

July 18, 2017 - By Marguerite Chambers

The chart of Jaguar Animal Health Inc (JAGX) shows a double bottom with $0.64 target or 9.00 % below today’s $0.70 share price. The 5 months chart pattern indicates high risk for the $12.29 million company. It was reported on Jul, 18 by Finviz.com. If the $0.64 price target is reached, the company will be worth $1.11M less. Double bottoms are rare but powerful chart patterns.

The stock increased 2.94% or $0.02 on July 17, reaching $0.7. About shares traded. Jaguar Animal Health Inc (NASDAQ:JAGX) has declined 48.63% since July 18, 2016 and is downtrending. It has underperformed by 65.33% the S&P500.

Jaguar Animal Health Inc (NASDAQ:JAGX) Ratings Coverage

Among 2 analysts covering Jaguar Animal Health (NASDAQ:JAGX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Jaguar Animal Health had 2 analyst reports since July 11, 2017 according to SRatingsIntel. H.C. Wainwright maintained the shares of JAGX in report on Tuesday, July 11 with “Buy” rating.

More notable recent Jaguar Animal Health Inc (NASDAQ:JAGX) news were published by: Reuters.com which released: “BRIEF-Jaguar Animal Health, Elanco US to license, develop, and commercialize …” on January 31, 2017, also Finance.Yahoo.com with their article: “Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement” published on March 31, 2017, Businesswire.com published: “Lisa Conte, CEO of Jaguar Animal Health and Napo Pharmaceuticals, to Present …” on May 25, 2017. More interesting news about Jaguar Animal Health Inc (NASDAQ:JAGX) were released by: Businesswire.com and their article: “Jaguar Animal Health and Napo Pharmaceuticals Announce Details for Proposed Merger” published on October 06, 2016 as well as Businesswire.com‘s news article titled: “Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to …” with publication date: July 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.